Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monovalent rAT
- Development stage
- Unknown
- Lead developer
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Monovalent rAT is a recombinant protein subunit vaccine candidate developed by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF). It consists of a detoxified version of the Staphylococcus aureus alpha-hemolysin (alpha-toxin, Hla), which is a critical virulence factor that forms pores in host cell membranes, leading to cell death and tissue damage. The vaccine is designed to stimulate the production of neutralizing antibodies that bind to and inactivate the alpha-toxin, thereby preventing or reducing the severity of S. aureus infections, including skin and soft tissue infections and invasive disease. It has been evaluated in Phase 1/2 clinical trials as both a standalone monovalent vaccine and as a component of a bivalent formulation alongside rLukS-PV.
- Other names
- rAT vaccinerecombinant alpha-toxin vaccineStaphylococcus aureus alpha-toxin toxoid
02
Targets
Hla (Staphylococcus aureus alpha toxin)
Beyond the preview
Go deeper on monovalent rAT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monovalent rAT.